Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: "Ohio Sen. Rob Portman has been busy in Washington touting the Comprehensive Addiction Recovery Act in response to a shocking number of heroin overdoses in Ohio. The bill just passed in the Senate, 94-1. (Nebraska Sen. Ben Sasse was the sole ""nay,"" saying he believes that fighting addiction is a local issue.) Ohio ranks high on the list of states reeling from the national epidemic. In Montgomery County, which encompasses Dayton, Ohio, heroin-related deaths increased 225 percent between 2011 and 2015. Back in the 1970s, the heroin on U.S. streets was the ""black tar"" variety, and much of it came from southeast Asia. In 2010, 80 percent of the heroin in the world came from poppy fields in Afghanistan, according to the Office of National Drug Control Policy. So when Portman said that most of the heroin in America comes from Mexico’s border, we were skeptical. Portman, it turns out, has done his homework. The Drug Enforcement Administration’s National Drug Threat Assessment of 2015 says that Mexico is the primary supplier of heroin to the United States. ""Southeast Asia was once the dominant supplier of heroin in the United States, but Southeast Asian heroin is now rarely detected in U.S. markets,"" the report state. ""Mexico and, to a lesser extent, Colombia dominate the U.S. heroin market, because of their proximity, established transportation and distribution infrastructure, and ability to satisfy U.S. heroin demand."" The report also says that Mexican ""transnational criminal organizations,"" (the DEA’s term for drug-dealing gangs) ""pose the greatest criminal drug threat to the United States; no other group is currently positioned to challenge them."" The National Drug Threat report notes that Colombian gangs were traditionally the suppliers of wholesale cocaine and heroin to Mexican and Dominican groups. But cartels in Mexico are ramping up their roles on the supply side -- opium production in Mexico increased by 50 percent in 2014. Mexican labs also produce fentanyl, a synthetic painkiller that is 80 to 100 times stronger than morphine. Fentanyl is sometimes mixed with heroin or substituted for heroin, and the DEA reports more than 700 overdoses attributed to fentanyl between late 2013 and early 2015. Drugs get past the U.S. borders mostly ""by land, not by sea,"" said Homeland Security Secretary Jeh Johnson, in the same March 8 hearing with Portman. And a 2015 Washington Post series on the surge of heroin puts the border detection rate at a scant 1.5 percent. Smugglers’ creativity defies gravity: One successful bust came when agents caught two men flying a drone carrying 28 pounds of heroin from Mexico to California. Our ruling Portman said that heroin is coming to the United States primarily from Mexico. He hasn’t been studying drug facts for nothing."
[EX A]: We understand that this heroin is primarily coming from Mexico, over the border.

[EX Q]: The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it’s understandable that they wouldn’t comment on it — and that’s why we’re rating this Not Applicable. But let’s be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug — even one from the FDA — will include some mention of cost in its message. This release gives the preliminary results from a single study of 310 patients. Because the drug is experimental, long-term results haven’t been studied. Of the 310 patients enrolled in the lone trial upon which the approval is based, 14.8 percent showed some shrinkage of tumors during the assessment period lasting from 2.1 to about 13.8 months. For a subset of patients who were classified as having a positive response to PD-L1 expression, the response was 26 percent. As noted above, tumor shrinkage doesn’t always lead to improvements in survival or quality of life. It is a surrogate endpoint — a substitute — for the main outcome which is survival. Although this drug looks promising, to be fully transparent about its benefits as currently known, the release should have explained this. As noted in the “Summary,” another larger study is underway to assess the drug’s impact on extending life and improving quality of life. The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are “immune-mediated.” We would have liked a bit more context on what this term means for patients. The release outlines that this is the very first clinical trial of this compound for safety and efficacy, and under which regulatory paths the drug was assessed, including “breakthrough therapy designation, priority review status and accelerated approval.” We’re giving this release the benefit of the doubt and rating it Satisfactory for its bare bones description of the trial (and since we already addressed the lack of long-term survival data in the “Benefits” section.) As it stands, the results from the small trial were preliminary and short-term and did not reflect long-term survival. We would have liked to see a reference or link to the completed trial where one could look at the results to assess independently or learn more about the outcomes. We think the release should have provided more data on the patient demographics, the treatment regimen (dosing amount and schedule) as well as the range in tumor reduction. There is no disease mongering. This release describes the approval of a new drug by a regulatory agency, but we’d still like to know who sponsored the study that’s the basis for the approval. It’s not enough to state who markets the drug. The release does not give us very much information about alternatives. These patients had already received other therapy and their cancer had recurred, so it is implied that they had no other alternatives. But this isn’t stated very clearly. We can assume (and it seems evident) that the platinum-based therapy that the patients didn’t respond to initially is the usual treatment. The FDA’s approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn’t state this explicitly but it can be inferred.) A NYT article said the drug would be available in about two months. The release clearly states this product is first of its kind for this type of cancer. We found no unjustifiable language.
[EX A]: FDA approves new, targeted treatment for bladder cancer

[EX Q]: Michael Phelps appears in “Angst” to share his story of being bullied and depressed, leading to severe anxiety. The swimmer, winner of 28 Olympic medals, would look in the mirror and not like what he saw. “Once I opened up about that and things that I had kept inside of me for so many years, I then found that life was a lot easier. I got to the point where I understood that it’s OK to not be OK,” he says in the film. “Angst,” an IndieFlix film designed to be screened at schools and community centers, features candid interviews with children and young adults discussing their anxiety, along with advice from mental health experts and resources and tools. Phelps is like a muscular explanation mark for what the filmmakers wanted to show — that even world champions can feel low. “I’m grateful because my mission with this film is to help make the world a better place and I believe he is so additive on that level,” said Scilla Andreen, CEO and co-founder of IndieFlix. “If we can introduce prevention, self-care and well-being to our children — even in the pre-K and kindergarten years — they can have a completely different life.” Andreen hopes the film will reach more than 3 million people around the world from 25,000 community and school screenings. “Angst” was filmed in the U.S. and United Kingdom and is appropriate for children starting at age 10. “Anxiety is totally treatable,” she said. “It can be a precursor to so many things that can then lead to addiction, homelessness, dropping out of school and a host of other mental health challenges.” Anxiety disorders are the most common mental health challenge in the U.S., impacting 54 percent of females and 46 percent of males, with age 7 being the median age of onset, according to the World Health Organization. The American College Health Association has found that undergraduates reporting “overwhelming anxiety” jumped to 62 percent in 2016 from 50 percent in 2011. “Talking about it is the most effective thing you can do and, of course, the last thing you want to do,” said Andreen. In addition to talking, writing about your feelings or connecting to music can help. “Anything that helps you to take a break from the anxiety and move the energy to the front of the brain.” Andreen, whose distribution streaming service embraces projects that push for social change, was bullied as a child and learned something about herself while working on the film. “Everyone has anxiety. And I learned in making the movie that I have social anxiety. I never even knew that. I just thought I was born less than everyone else and that was my lot in life. I would always have to work harder, try harder, never fit in,” she said. “I don’t feel so alone.” In addition to the documentary, IndieFlix is creating a web-based series on anxiety to dig deeper into the issue and has produced a virtual reality component that allows users to experience a panic attack firsthand. Andreen believes anxiety levels are so high in part because of the pace of modern life and the amount of time people spend with their electronic devices, which takes away from connecting in person and developing empathy. “We need more face time with each other,” said Andreen, a former Emmy-nominated costume designer. “We just stopped doing it. We’re out of practice, that’s all.” ___ Online: Film: http://angstmovie.com See Phelps: https://vimeo.com/234937898 __ Mark Kennedy is at http://twitter.com/KennedyTwits
[EX A]:
Documentary about anxiety taps a world-class athlete.